9 Induced pluripotent stem cell-derived endothelial cells from human diabetic donors carry an imprint of the diabetic milieu
Diabetic endotheliopathy is the main cause for impaired angiogenesis and reduced neovascularization that lead to microvascular injury and vascular complications. The pathogenic basis for vascular complications arising from diabetes is complex. Elucidation of key underlying mechanisms will help the d...
Gespeichert in:
| Veröffentlicht in: | Heart (British Cardiac Society) 2021-06, Vol.107 (Suppl 1), p.A7-A7 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | A7 |
|---|---|
| container_issue | Suppl 1 |
| container_start_page | A7 |
| container_title | Heart (British Cardiac Society) |
| container_volume | 107 |
| creator | Eleftheriadou, Magdalini Meskin, Hojjat Naderi Yacoub, Andrew Morrison, Thomas Cornelius, Victoria Yang, Chunbo Gonzalez, Martha Kelaini, Sophia Carney, Garret Campos, Guillermo Lopez Lois, Noemi Grieve, David Stitt, Alan Margariti, Andriana |
| description | Diabetic endotheliopathy is the main cause for impaired angiogenesis and reduced neovascularization that lead to microvascular injury and vascular complications. The pathogenic basis for vascular complications arising from diabetes is complex. Elucidation of key underlying mechanisms will help the development of novel therapies and the discovery of potential biomarkers. The ability to generate functional endothelial cells (ECs) from induced pluripotent stem cells (iPSCs) from small amounts of blood is a novel and powerful tool for cell-based therapies. Human iPSC-derived ECs (iPS-ECs) have a broad range of clinical applications including cell-based therapy, disease modelling and drug screening; they can be used in mechanistic studies towards the development of novel therapies and in the discovery of new biomarkers to be applied in regenerative medicine and treatment of diabetic vasculopathy. Here we utilize transcriptomic and proteomic technologies to assess patient-specific iPS-ECs from diabetic (DiPS-ECs) and non-diabetic (NiPS-ECS) donors 1,2,3,4 in order to investigate the mechanisms driving endotheliopathy in diabetes. Our in vitro and in vivo models recapitulate the effects of hyperglycaemia on the vasculature in the clinical setting. RNA-seq data showed that genes and proteins involved in angiogenesis and EC function were significantly downregulated in DiPS-ECs in comparison to NiPS-ECS (n=3, p |
| doi_str_mv | 10.1136/heartjnl-2021-BCS.9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2537060273</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2537060273</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1129-22debc70868a4a14e594765216532d9c97c6ee1aa7066088daa9d87eb0c0d3f73</originalsourceid><addsrcrecordid>eNpFkE1LxDAQhoMouK7-Ai8Bz13z0abNURc_FhY8qOAtpMmUTUk_TFthL-LFP-ovMesqnmaY931nhgehc0oWlHJxuQEdxrr1CSOMJtfLx4U8QDOaiiJO6Mth7HmWJYLw_BidDENNCEllIWboXX59fK5aOxmwuPdTcH03QjviYYQGG_A-sRDcW1Shtd24Ae-0_xEGXIWuwZup0S22TpcwOoNt13ZhwEaHsMVRcE0fXNzXVTiG_32N8w6mU3RUaT_A2W-do-fbm6flfbJ-uFstr9ZJSSmTCWMWSpOTQhQ61TSFTKa5yBgVGWdWGpkbAUC1zokQpCis1tIWOZTEEMurnM_RxX5vH7rXCYZR1d0U2nhSsYzHFGE5j67F3lU2tYpvNzpsFSVqx1j9MVY7xioyVpJ_A0ZzdKE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2537060273</pqid></control><display><type>article</type><title>9 Induced pluripotent stem cell-derived endothelial cells from human diabetic donors carry an imprint of the diabetic milieu</title><source>PubMed Central</source><creator>Eleftheriadou, Magdalini ; Meskin, Hojjat Naderi ; Yacoub, Andrew ; Morrison, Thomas ; Cornelius, Victoria ; Yang, Chunbo ; Gonzalez, Martha ; Kelaini, Sophia ; Carney, Garret ; Campos, Guillermo Lopez ; Lois, Noemi ; Grieve, David ; Stitt, Alan ; Margariti, Andriana</creator><creatorcontrib>Eleftheriadou, Magdalini ; Meskin, Hojjat Naderi ; Yacoub, Andrew ; Morrison, Thomas ; Cornelius, Victoria ; Yang, Chunbo ; Gonzalez, Martha ; Kelaini, Sophia ; Carney, Garret ; Campos, Guillermo Lopez ; Lois, Noemi ; Grieve, David ; Stitt, Alan ; Margariti, Andriana</creatorcontrib><description>Diabetic endotheliopathy is the main cause for impaired angiogenesis and reduced neovascularization that lead to microvascular injury and vascular complications. The pathogenic basis for vascular complications arising from diabetes is complex. Elucidation of key underlying mechanisms will help the development of novel therapies and the discovery of potential biomarkers. The ability to generate functional endothelial cells (ECs) from induced pluripotent stem cells (iPSCs) from small amounts of blood is a novel and powerful tool for cell-based therapies. Human iPSC-derived ECs (iPS-ECs) have a broad range of clinical applications including cell-based therapy, disease modelling and drug screening; they can be used in mechanistic studies towards the development of novel therapies and in the discovery of new biomarkers to be applied in regenerative medicine and treatment of diabetic vasculopathy. Here we utilize transcriptomic and proteomic technologies to assess patient-specific iPS-ECs from diabetic (DiPS-ECs) and non-diabetic (NiPS-ECS) donors 1,2,3,4 in order to investigate the mechanisms driving endotheliopathy in diabetes. Our in vitro and in vivo models recapitulate the effects of hyperglycaemia on the vasculature in the clinical setting. RNA-seq data showed that genes and proteins involved in angiogenesis and EC function were significantly downregulated in DiPS-ECs in comparison to NiPS-ECS (n=3, p<0.05). Specific epsins regulating VEGF-mediated angiogenesis were downregulated in DiPS-ECs, leading to increased signalling VEGF pathway activation6. Moreover factors involved in E-cadherin signalling, endothelial-to-mesenchymal transition and fibrosis were increased in DiPS-ECs. We detected abnormal capillary permeability and barrier integrity in DiPS-ECs using xCELLigence®. DiPS-ECs had significantly reduced barrier integrity and barrier recovery (n=3, p<0.001, ±SEM) and also displayed impaired tube formation in vitro (n=3, ±SEM, p<0.05). DiPS-ECs displayed impaired function demonstrated by decreased blood flow recovery (BFR) compared to NiPS ECs (n=3) when injected to the hindlimb of mice following femoral artery ligation. Finally, our proteomic and transcriptomic analysis confirmed imbalances in several angiogenic genes including endothelial specific Roundabout protein 4 (ROBO4) that is highly involved in pathways related to angiogenesis, barrier stability and endothelial health 7. Expression of ROBO4 was found to be impaired in DiPS-ECs and transcriptomic analysis along with in vitro and in vivo studies revealed its importance in vascular development and angiogenesis. Our data support the impaired angiogenic functionality of DiPS-ECs cells in vitro and in vivo and show that DiPS-ECs carry an imprint of the diabetic milieu which is reflected in their dysfunction. To the best of our knowledge, we have identified a novel disease-specific signature in diabetic iPS-ECs, therefore our human iPS-EC model may serve as a valuable tool to study biological pathways and identify new treatments for diabetes-induced endotheliopathy.Conflict of InterestNone</description><identifier>ISSN: 1355-6037</identifier><identifier>EISSN: 1468-201X</identifier><identifier>DOI: 10.1136/heartjnl-2021-BCS.9</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Angiogenesis ; Biomarkers ; Diabetes ; Regenerative medicine</subject><ispartof>Heart (British Cardiac Society), 2021-06, Vol.107 (Suppl 1), p.A7-A7</ispartof><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Eleftheriadou, Magdalini</creatorcontrib><creatorcontrib>Meskin, Hojjat Naderi</creatorcontrib><creatorcontrib>Yacoub, Andrew</creatorcontrib><creatorcontrib>Morrison, Thomas</creatorcontrib><creatorcontrib>Cornelius, Victoria</creatorcontrib><creatorcontrib>Yang, Chunbo</creatorcontrib><creatorcontrib>Gonzalez, Martha</creatorcontrib><creatorcontrib>Kelaini, Sophia</creatorcontrib><creatorcontrib>Carney, Garret</creatorcontrib><creatorcontrib>Campos, Guillermo Lopez</creatorcontrib><creatorcontrib>Lois, Noemi</creatorcontrib><creatorcontrib>Grieve, David</creatorcontrib><creatorcontrib>Stitt, Alan</creatorcontrib><creatorcontrib>Margariti, Andriana</creatorcontrib><title>9 Induced pluripotent stem cell-derived endothelial cells from human diabetic donors carry an imprint of the diabetic milieu</title><title>Heart (British Cardiac Society)</title><description>Diabetic endotheliopathy is the main cause for impaired angiogenesis and reduced neovascularization that lead to microvascular injury and vascular complications. The pathogenic basis for vascular complications arising from diabetes is complex. Elucidation of key underlying mechanisms will help the development of novel therapies and the discovery of potential biomarkers. The ability to generate functional endothelial cells (ECs) from induced pluripotent stem cells (iPSCs) from small amounts of blood is a novel and powerful tool for cell-based therapies. Human iPSC-derived ECs (iPS-ECs) have a broad range of clinical applications including cell-based therapy, disease modelling and drug screening; they can be used in mechanistic studies towards the development of novel therapies and in the discovery of new biomarkers to be applied in regenerative medicine and treatment of diabetic vasculopathy. Here we utilize transcriptomic and proteomic technologies to assess patient-specific iPS-ECs from diabetic (DiPS-ECs) and non-diabetic (NiPS-ECS) donors 1,2,3,4 in order to investigate the mechanisms driving endotheliopathy in diabetes. Our in vitro and in vivo models recapitulate the effects of hyperglycaemia on the vasculature in the clinical setting. RNA-seq data showed that genes and proteins involved in angiogenesis and EC function were significantly downregulated in DiPS-ECs in comparison to NiPS-ECS (n=3, p<0.05). Specific epsins regulating VEGF-mediated angiogenesis were downregulated in DiPS-ECs, leading to increased signalling VEGF pathway activation6. Moreover factors involved in E-cadherin signalling, endothelial-to-mesenchymal transition and fibrosis were increased in DiPS-ECs. We detected abnormal capillary permeability and barrier integrity in DiPS-ECs using xCELLigence®. DiPS-ECs had significantly reduced barrier integrity and barrier recovery (n=3, p<0.001, ±SEM) and also displayed impaired tube formation in vitro (n=3, ±SEM, p<0.05). DiPS-ECs displayed impaired function demonstrated by decreased blood flow recovery (BFR) compared to NiPS ECs (n=3) when injected to the hindlimb of mice following femoral artery ligation. Finally, our proteomic and transcriptomic analysis confirmed imbalances in several angiogenic genes including endothelial specific Roundabout protein 4 (ROBO4) that is highly involved in pathways related to angiogenesis, barrier stability and endothelial health 7. Expression of ROBO4 was found to be impaired in DiPS-ECs and transcriptomic analysis along with in vitro and in vivo studies revealed its importance in vascular development and angiogenesis. Our data support the impaired angiogenic functionality of DiPS-ECs cells in vitro and in vivo and show that DiPS-ECs carry an imprint of the diabetic milieu which is reflected in their dysfunction. To the best of our knowledge, we have identified a novel disease-specific signature in diabetic iPS-ECs, therefore our human iPS-EC model may serve as a valuable tool to study biological pathways and identify new treatments for diabetes-induced endotheliopathy.Conflict of InterestNone</description><subject>Angiogenesis</subject><subject>Biomarkers</subject><subject>Diabetes</subject><subject>Regenerative medicine</subject><issn>1355-6037</issn><issn>1468-201X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpFkE1LxDAQhoMouK7-Ai8Bz13z0abNURc_FhY8qOAtpMmUTUk_TFthL-LFP-ovMesqnmaY931nhgehc0oWlHJxuQEdxrr1CSOMJtfLx4U8QDOaiiJO6Mth7HmWJYLw_BidDENNCEllIWboXX59fK5aOxmwuPdTcH03QjviYYQGG_A-sRDcW1Shtd24Ae-0_xEGXIWuwZup0S22TpcwOoNt13ZhwEaHsMVRcE0fXNzXVTiG_32N8w6mU3RUaT_A2W-do-fbm6flfbJ-uFstr9ZJSSmTCWMWSpOTQhQ61TSFTKa5yBgVGWdWGpkbAUC1zokQpCis1tIWOZTEEMurnM_RxX5vH7rXCYZR1d0U2nhSsYzHFGE5j67F3lU2tYpvNzpsFSVqx1j9MVY7xioyVpJ_A0ZzdKE</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Eleftheriadou, Magdalini</creator><creator>Meskin, Hojjat Naderi</creator><creator>Yacoub, Andrew</creator><creator>Morrison, Thomas</creator><creator>Cornelius, Victoria</creator><creator>Yang, Chunbo</creator><creator>Gonzalez, Martha</creator><creator>Kelaini, Sophia</creator><creator>Carney, Garret</creator><creator>Campos, Guillermo Lopez</creator><creator>Lois, Noemi</creator><creator>Grieve, David</creator><creator>Stitt, Alan</creator><creator>Margariti, Andriana</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>202106</creationdate><title>9 Induced pluripotent stem cell-derived endothelial cells from human diabetic donors carry an imprint of the diabetic milieu</title><author>Eleftheriadou, Magdalini ; Meskin, Hojjat Naderi ; Yacoub, Andrew ; Morrison, Thomas ; Cornelius, Victoria ; Yang, Chunbo ; Gonzalez, Martha ; Kelaini, Sophia ; Carney, Garret ; Campos, Guillermo Lopez ; Lois, Noemi ; Grieve, David ; Stitt, Alan ; Margariti, Andriana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1129-22debc70868a4a14e594765216532d9c97c6ee1aa7066088daa9d87eb0c0d3f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Angiogenesis</topic><topic>Biomarkers</topic><topic>Diabetes</topic><topic>Regenerative medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eleftheriadou, Magdalini</creatorcontrib><creatorcontrib>Meskin, Hojjat Naderi</creatorcontrib><creatorcontrib>Yacoub, Andrew</creatorcontrib><creatorcontrib>Morrison, Thomas</creatorcontrib><creatorcontrib>Cornelius, Victoria</creatorcontrib><creatorcontrib>Yang, Chunbo</creatorcontrib><creatorcontrib>Gonzalez, Martha</creatorcontrib><creatorcontrib>Kelaini, Sophia</creatorcontrib><creatorcontrib>Carney, Garret</creatorcontrib><creatorcontrib>Campos, Guillermo Lopez</creatorcontrib><creatorcontrib>Lois, Noemi</creatorcontrib><creatorcontrib>Grieve, David</creatorcontrib><creatorcontrib>Stitt, Alan</creatorcontrib><creatorcontrib>Margariti, Andriana</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Heart (British Cardiac Society)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eleftheriadou, Magdalini</au><au>Meskin, Hojjat Naderi</au><au>Yacoub, Andrew</au><au>Morrison, Thomas</au><au>Cornelius, Victoria</au><au>Yang, Chunbo</au><au>Gonzalez, Martha</au><au>Kelaini, Sophia</au><au>Carney, Garret</au><au>Campos, Guillermo Lopez</au><au>Lois, Noemi</au><au>Grieve, David</au><au>Stitt, Alan</au><au>Margariti, Andriana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>9 Induced pluripotent stem cell-derived endothelial cells from human diabetic donors carry an imprint of the diabetic milieu</atitle><jtitle>Heart (British Cardiac Society)</jtitle><date>2021-06</date><risdate>2021</risdate><volume>107</volume><issue>Suppl 1</issue><spage>A7</spage><epage>A7</epage><pages>A7-A7</pages><issn>1355-6037</issn><eissn>1468-201X</eissn><abstract>Diabetic endotheliopathy is the main cause for impaired angiogenesis and reduced neovascularization that lead to microvascular injury and vascular complications. The pathogenic basis for vascular complications arising from diabetes is complex. Elucidation of key underlying mechanisms will help the development of novel therapies and the discovery of potential biomarkers. The ability to generate functional endothelial cells (ECs) from induced pluripotent stem cells (iPSCs) from small amounts of blood is a novel and powerful tool for cell-based therapies. Human iPSC-derived ECs (iPS-ECs) have a broad range of clinical applications including cell-based therapy, disease modelling and drug screening; they can be used in mechanistic studies towards the development of novel therapies and in the discovery of new biomarkers to be applied in regenerative medicine and treatment of diabetic vasculopathy. Here we utilize transcriptomic and proteomic technologies to assess patient-specific iPS-ECs from diabetic (DiPS-ECs) and non-diabetic (NiPS-ECS) donors 1,2,3,4 in order to investigate the mechanisms driving endotheliopathy in diabetes. Our in vitro and in vivo models recapitulate the effects of hyperglycaemia on the vasculature in the clinical setting. RNA-seq data showed that genes and proteins involved in angiogenesis and EC function were significantly downregulated in DiPS-ECs in comparison to NiPS-ECS (n=3, p<0.05). Specific epsins regulating VEGF-mediated angiogenesis were downregulated in DiPS-ECs, leading to increased signalling VEGF pathway activation6. Moreover factors involved in E-cadherin signalling, endothelial-to-mesenchymal transition and fibrosis were increased in DiPS-ECs. We detected abnormal capillary permeability and barrier integrity in DiPS-ECs using xCELLigence®. DiPS-ECs had significantly reduced barrier integrity and barrier recovery (n=3, p<0.001, ±SEM) and also displayed impaired tube formation in vitro (n=3, ±SEM, p<0.05). DiPS-ECs displayed impaired function demonstrated by decreased blood flow recovery (BFR) compared to NiPS ECs (n=3) when injected to the hindlimb of mice following femoral artery ligation. Finally, our proteomic and transcriptomic analysis confirmed imbalances in several angiogenic genes including endothelial specific Roundabout protein 4 (ROBO4) that is highly involved in pathways related to angiogenesis, barrier stability and endothelial health 7. Expression of ROBO4 was found to be impaired in DiPS-ECs and transcriptomic analysis along with in vitro and in vivo studies revealed its importance in vascular development and angiogenesis. Our data support the impaired angiogenic functionality of DiPS-ECs cells in vitro and in vivo and show that DiPS-ECs carry an imprint of the diabetic milieu which is reflected in their dysfunction. To the best of our knowledge, we have identified a novel disease-specific signature in diabetic iPS-ECs, therefore our human iPS-EC model may serve as a valuable tool to study biological pathways and identify new treatments for diabetes-induced endotheliopathy.Conflict of InterestNone</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/heartjnl-2021-BCS.9</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-6037 |
| ispartof | Heart (British Cardiac Society), 2021-06, Vol.107 (Suppl 1), p.A7-A7 |
| issn | 1355-6037 1468-201X |
| language | eng |
| recordid | cdi_proquest_journals_2537060273 |
| source | PubMed Central |
| subjects | Angiogenesis Biomarkers Diabetes Regenerative medicine |
| title | 9 Induced pluripotent stem cell-derived endothelial cells from human diabetic donors carry an imprint of the diabetic milieu |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T20%3A04%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=9%E2%80%85Induced%20pluripotent%20stem%20cell-derived%20endothelial%20cells%20from%20human%20diabetic%20donors%20carry%20an%20imprint%20of%20the%20diabetic%20milieu&rft.jtitle=Heart%20(British%20Cardiac%20Society)&rft.au=Eleftheriadou,%20Magdalini&rft.date=2021-06&rft.volume=107&rft.issue=Suppl%201&rft.spage=A7&rft.epage=A7&rft.pages=A7-A7&rft.issn=1355-6037&rft.eissn=1468-201X&rft_id=info:doi/10.1136/heartjnl-2021-BCS.9&rft_dat=%3Cproquest_bmj_p%3E2537060273%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2537060273&rft_id=info:pmid/&rfr_iscdi=true |